Gain new key opinion leader (KOL) insights on the latest events happening in COPD.
Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate), delivered via PARI's investigational eFlow nebuliser system. The KOLs also imparted their expectations for the US launch of a generic version of GlaxoSmithKline’s Advair Diskus following the acceptance of Sandoz’s Abbreviated New Drug Application (ANDA) for its fluticasone propionate/salmeterol combination product. Finally, the experts shared their views on the updated National Institute for Health and Care Excellence (NICE) recommendations for AstraZeneca’s oral phosphodiesterase type 4 (PDE4) inhibitor Daxas (roflumilast).
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved